Randomized phase 2 study of mFOLFOX6 plus bevacizumab versus modified OPTIMOX plus bevacizumab for metastatic colorectal cancer
- Conditions
- colorectal cancer
- Registration Number
- JPRN-UMIN000003477
- Lead Sponsor
- Chiba Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 80
Not provided
1) contraindication to 5-FU, oxaliplatin, UFT, calcium folinate, or bevacizumab. 2) moderate/severe pleural effusion, ascites or pericardial effusion. 3) brain metastases. 4) history of active other malignancies. 5) neuropathy. 6) history of thoromboembolitic disease. 7) uncontrollable Diabetes Mellitus or hypertension 8) interstitial lung disease, pulmonary fibrosis or severe pulmonary emphysema. 9) intestinal bleeding, ileus, bowel obstruction or uncontrolled peptic ulcer. 10) clinically significant infectious disease (body temperature more than 38.0 degrees) 11) urinary protein (more than 1+) 12) uncontrolled watery diarrhea. 13) pregnant or lactating women, women who are capable of pregnancy or intend to get pregnant. 14) Any other cases who are regarded as inadequate for study enrollment by the attending doctors.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method